Incidence and Risk Factors of Acute Pancreatitis Following Endoscopic Ultrasound-Guided Fine Needle Biopsy (EUS-FNB)

What this Trial Is About

Researchers are investigating how often acute pancreatitis occurs after Endoscopic Ultrasonography-guided Fine Needle Biopsy (EUS-FNB) in patients with pancreatic and biliary tract diseases. This observational study aims to identify risk factors for pancreatitis following EUS-FNB to improve clinical care, reduce complications, lower treatment costs, and enhance diagnostic accuracy. The study will focus on patients treated at Shariati Hospital in Tehran, assessing post-procedure outcomes to provide better management of pancreatic and biliary diseases. The study involves collecting demographic and clinical data from patients undergoing EUS-guided FNB on lesions in the pancreas, ampulla of Vater, or distal common bile duct. Amylase and lipase blood levels will be tested 24 hours after the procedure to help diagnose pancreatitis, which is identified based on abdominal pain and enzyme levels three times above the normal range. An expert gastroenterologist not involved in the biopsies will review medical records to confirm cases, using consensus guidelines but applying clinical judgment when needed. Patients will be followed up by phone 24 to 72 hours after the procedure to monitor complications. Participants will undergo clinical interviews, examinations, and record reviews to gather information such as age, gender, biopsy details, and history of pancreatitis. Outcomes include measuring the incidence of pancreatitis up to three days post-biopsy and assessing associated risk factors. Those who develop pancreatitis will receive standard care and follow-up. The study plans to enroll at least 300 patients, with monitoring continuing up to one week for moderate to severe pancreatitis cases.

EUS-guided FNB-induced PANCREatitis Assessment